Be on the lookout for a price bounce soon.
The RSI Indicator shows that the ticker has stayed in the oversold zone for 3 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an Uptrend is expected.
The Moving Average Convergence Divergence (MACD) for GLAS just turned positive on October 28, 2026. Looking at past instances where GLAS's MACD turned positive, the stock continued to rise in 27 of 36 cases over the following month. The odds of a continued upward trend are 75%.
GLAS may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Momentum Indicator moved below the 0 level on November 05, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on GLAS as a result. In 69 of 82 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 84%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where GLAS declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 88%.
The Aroon Indicator for GLAS entered a downward trend on October 28, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron PE Growth Rating for this company is 6 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 40 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.699) is normal, around the industry mean (6.379). P/E Ratio (-2.737) is within average values for comparable stocks, (0.548). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.202). Dividend Yield (0.000) settles around the average of (0.062) among similar stocks. P/S Ratio (3.880) is also within normal values, averaging (183.387).
The Tickeron Price Growth Rating for this company is 96 (best 1 - 100 worst), indicating slightly worse than average price growth. GLAS’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. GLAS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 83, placing this stock worse than average.
The RSI Oscillator for OPTH moved into overbought territory on November 10, 2026. Be on the watch for a price drop or consolidation in the future -- when this happens, think about selling the stock or exploring put options.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 54 of 66 cases where OPTH's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 82%.
The Moving Average Convergence Divergence (MACD) for OPTH just turned positive on November 10, 2026. Looking at past instances where OPTH's MACD turned positive, the stock continued to rise in 42 of 56 cases over the following month. The odds of a continued upward trend are 75%.
Following a +13.27% 3-day Advance, the price is estimated to grow further. Considering data from situations where OPTH advanced for three days, in 172 of 201 cases, the price rose further within the following month. The odds of a continued upward trend are 86%.
OPTH may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where OPTH declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 87%.
The Aroon Indicator for OPTH entered a downward trend on November 10, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron PE Growth Rating for this company is 9 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 34 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.760) is normal, around the industry mean (6.379). P/E Ratio (-1.164) is within average values for comparable stocks, (0.548). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.202). Dividend Yield (0.000) settles around the average of (0.062) among similar stocks. P/S Ratio (135.135) is also within normal values, averaging (183.387).
The Tickeron Price Growth Rating for this company is 34 (best 1 - 100 worst), indicating steady price growth. OPTH’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 70 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. OPTH’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 83, placing this stock better than average.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
GLAS | ||
|---|---|---|
OUTLOOK RATING 1..100 | 2 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 40 Fair valued | |
PROFIT vs RISK RATING 1..100 | 100 | |
SMR RATING 1..100 | 98 | |
PRICE GROWTH RATING 1..100 | 96 | |
P/E GROWTH RATING 1..100 | 6 | |
SEASONALITY SCORE 1..100 | 85 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
| GLAS | OPTH | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 66% | 2 days ago 90% |
| Stochastic ODDS (%) | 2 days ago 78% | 2 days ago 82% |
| Momentum ODDS (%) | 2 days ago 84% | N/A |
| MACD ODDS (%) | 2 days ago 75% | 2 days ago 75% |
| TrendWeek ODDS (%) | 2 days ago 88% | 2 days ago 81% |
| TrendMonth ODDS (%) | 2 days ago 89% | 2 days ago 90% |
| Advances ODDS (%) | N/A | 7 days ago 86% |
| Declines ODDS (%) | 3 days ago 88% | 9 days ago 87% |
| BollingerBands ODDS (%) | 2 days ago 74% | 2 days ago 90% |
| Aroon ODDS (%) | 2 days ago 89% | 2 days ago 90% |
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
GLAS’s FA Score shows that 1 FA rating(s) are green while OPTH’s FA Score has 1 green FA rating(s).
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
GLAS’s TA Score shows that 4 TA indicator(s) are bullish while OPTH’s TA Score has 5 bullish TA indicator(s).
GLAS (@Pharmaceuticals: Generic) experienced а -15.81% price change this week, while OPTH (@Pharmaceuticals: Generic) price change was +6.87% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was -0.20%. For the same industry, the average monthly price growth was -6.54%, and the average quarterly price growth was +10.31%.
GLAS is expected to report earnings on Nov 11, 2026.
OPTH is expected to report earnings on Nov 13, 2026.
A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.
A.I.dvisor indicates that over the last year, GLAS has been loosely correlated with TRLV. These tickers have moved in lockstep 64% of the time. This A.I.-generated data suggests there is some statistical probability that if GLAS jumps, then TRLV could also see price increases.
| Ticker / NAME | Correlation To GLAS | 1D Price Change % | ||
|---|---|---|---|---|
| GLAS | 100% | +2.60% | ||
| TRLV - GLAS | 64% Loosely correlated | +0.73% | ||
| CGC - GLAS | 63% Loosely correlated | -4.88% | ||
| TLRY - GLAS | 53% Loosely correlated | -7.02% | ||
| ACB - GLAS | 50% Loosely correlated | -0.97% | ||
| OGI - GLAS | 47% Loosely correlated | -2.69% | ||
More | ||||
A.I.dvisor tells us that OPTH and GELS have been poorly correlated (+8% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that OPTH and GELS's prices will move in lockstep.
| Ticker / NAME | Correlation To OPTH | 1D Price Change % | ||
|---|---|---|---|---|
| OPTH | 100% | -9.80% | ||
| GELS - OPTH | 8% Poorly correlated | -6.12% | ||
| GLAS - OPTH | 6% Poorly correlated | +2.60% | ||
| AKAN - OPTH | 4% Poorly correlated | -8.85% | ||
| HLN - OPTH | 3% Poorly correlated | +1.00% | ||
| ALVO - OPTH | 3% Poorly correlated | +4.05% | ||
More | ||||
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| FHLC | 90.20 | 0.16 | +0.18% |
| Fidelity MSCI Health Care Index ETF (FHLC) | |||
| GLRY | 37.68 | 0.05 | +0.13% |
| Inspire Growth ETF (GLRY) | |||
| FRIZ | 27.79 | N/A | N/A |
| Franklin Dividend Growth ETF (FRIZ) | |||
| CPRJ | 27.50 | -0.03 | -0.11% |
| Calamos Russell 2000 Structured Alt Protection ETF July (CPRJ) | |||
| FNY | 98.31 | -0.45 | -0.46% |
| First Trust Mid Cap Growth AlphaDEX Fund (FNY) | |||